Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs

Minna T. Jänis, Reijo Laaksonen, Matej Oresic

Research output: Contribution to journalArticleScientificpeer-review

11 Citations (Scopus)

Abstract

Background: The number of patients eligible for cardiovascular therapies in general is forecast to increase substantially in the coming decades. However, the current list of potential future cardiovascular blockbuster drugs is alarmingly short. There is thus a clear need for innovative strategies to increase the efficiency of drug development pipelines by establishing new sensitive biomarkers to monitor drug efficacy and safety in the context of complexity of lipoprotein metabolism targeted by the cardiovascular drugs. Methods: Metabolomics is a discipline dedicated to the systematic study of small molecules in cells, tissues and biofluids. Since lipids (including cholesterol), as well as other metabolites, are key constituents of lipoprotein particles and are thus part of the complex lipoprotein metabolism that includes exchange of lipids and metabolites with peripheral tissues, cardiovascular drug safety and efficacy needs to be addressed in the context of systemic lipid metabolism. Results/conclusion: Metabolomics, lipidomics in particular, is expected to make an important impact on the discovery and development of cardiovascular therapies.
Original languageEnglish
Pages (from-to)665-680
Number of pages16
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume4
Issue number6
DOIs
Publication statusPublished - 2008
MoE publication typeA1 Journal article-refereed

Fingerprint

Cardiovascular Agents
Metabolomics
Lipoproteins
Tissue
Metabolites
Metabolism
Lipids
Safety
Biomarkers
Lipid Metabolism
Pharmaceutical Preparations
Pipelines
Cholesterol
Molecules
Therapeutics

Keywords

  • cardiovascular disease
  • drug safety
  • lipid-lowering drugs
  • lipidomics
  • metabolomics
  • myopathy
  • pathway analysis
  • pharmacology
  • statins
  • toxicology
  • translational medicine

Cite this

Jänis, Minna T. ; Laaksonen, Reijo ; Oresic, Matej. / Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs. In: Expert Opinion on Drug Metabolism and Toxicology. 2008 ; Vol. 4, No. 6. pp. 665-680.
@article{76d84bb1ea1d455eb1234d2cfd0eee64,
title = "Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs",
abstract = "Background: The number of patients eligible for cardiovascular therapies in general is forecast to increase substantially in the coming decades. However, the current list of potential future cardiovascular blockbuster drugs is alarmingly short. There is thus a clear need for innovative strategies to increase the efficiency of drug development pipelines by establishing new sensitive biomarkers to monitor drug efficacy and safety in the context of complexity of lipoprotein metabolism targeted by the cardiovascular drugs. Methods: Metabolomics is a discipline dedicated to the systematic study of small molecules in cells, tissues and biofluids. Since lipids (including cholesterol), as well as other metabolites, are key constituents of lipoprotein particles and are thus part of the complex lipoprotein metabolism that includes exchange of lipids and metabolites with peripheral tissues, cardiovascular drug safety and efficacy needs to be addressed in the context of systemic lipid metabolism. Results/conclusion: Metabolomics, lipidomics in particular, is expected to make an important impact on the discovery and development of cardiovascular therapies.",
keywords = "cardiovascular disease, drug safety, lipid-lowering drugs, lipidomics, metabolomics, myopathy, pathway analysis, pharmacology, statins, toxicology, translational medicine",
author = "J{\"a}nis, {Minna T.} and Reijo Laaksonen and Matej Oresic",
year = "2008",
doi = "10.1517/17425255.4.6.665",
language = "English",
volume = "4",
pages = "665--680",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor & Francis",
number = "6",

}

Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs. / Jänis, Minna T.; Laaksonen, Reijo ; Oresic, Matej.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, No. 6, 2008, p. 665-680.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs

AU - Jänis, Minna T.

AU - Laaksonen, Reijo

AU - Oresic, Matej

PY - 2008

Y1 - 2008

N2 - Background: The number of patients eligible for cardiovascular therapies in general is forecast to increase substantially in the coming decades. However, the current list of potential future cardiovascular blockbuster drugs is alarmingly short. There is thus a clear need for innovative strategies to increase the efficiency of drug development pipelines by establishing new sensitive biomarkers to monitor drug efficacy and safety in the context of complexity of lipoprotein metabolism targeted by the cardiovascular drugs. Methods: Metabolomics is a discipline dedicated to the systematic study of small molecules in cells, tissues and biofluids. Since lipids (including cholesterol), as well as other metabolites, are key constituents of lipoprotein particles and are thus part of the complex lipoprotein metabolism that includes exchange of lipids and metabolites with peripheral tissues, cardiovascular drug safety and efficacy needs to be addressed in the context of systemic lipid metabolism. Results/conclusion: Metabolomics, lipidomics in particular, is expected to make an important impact on the discovery and development of cardiovascular therapies.

AB - Background: The number of patients eligible for cardiovascular therapies in general is forecast to increase substantially in the coming decades. However, the current list of potential future cardiovascular blockbuster drugs is alarmingly short. There is thus a clear need for innovative strategies to increase the efficiency of drug development pipelines by establishing new sensitive biomarkers to monitor drug efficacy and safety in the context of complexity of lipoprotein metabolism targeted by the cardiovascular drugs. Methods: Metabolomics is a discipline dedicated to the systematic study of small molecules in cells, tissues and biofluids. Since lipids (including cholesterol), as well as other metabolites, are key constituents of lipoprotein particles and are thus part of the complex lipoprotein metabolism that includes exchange of lipids and metabolites with peripheral tissues, cardiovascular drug safety and efficacy needs to be addressed in the context of systemic lipid metabolism. Results/conclusion: Metabolomics, lipidomics in particular, is expected to make an important impact on the discovery and development of cardiovascular therapies.

KW - cardiovascular disease

KW - drug safety

KW - lipid-lowering drugs

KW - lipidomics

KW - metabolomics

KW - myopathy

KW - pathway analysis

KW - pharmacology

KW - statins

KW - toxicology

KW - translational medicine

U2 - 10.1517/17425255.4.6.665

DO - 10.1517/17425255.4.6.665

M3 - Article

VL - 4

SP - 665

EP - 680

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 6

ER -